Brain tumors and therapies
We are committed to developing immunotherapies for brain tumors that are effective and selective. We use mice as experimental subjects because much is know about their immune system, and the murine system closely parallels the human immune system. When properly activated, the immune system has the characteristics of an ideal therapy: potent, precise killing of altered cells. But there is much to be learned about how to activate, direct, and control the immune response, particularly against tumors within the brain. We focus mostly on T cell mediated immune responses, and collaborate with investigators in microbiology, materials science, and engineering. Our recent work focuses on using oncolytic viruses to deliver genes expressing cytokines that strengthen the immune response locally within the tumor.
Tosic, V, Thomas, DL, Kranz, DM, Liu, J, McFadden, G, Shisler, JL, MacNeill, AL, and Roy, EJ. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. PlosOne 16;9( (2014).
Soto CM, Stone JD, Chervin AS, Engels B, Schreiber H, Roy EJ, Kranz DM. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother. 62 (2013) 359-69.
Chervin, A.S., Stone, Soto, C.M., Engels, B., Schreiber, H., Roy, E.J., Kranz, D.M. Design of T cell receptor libraries with diverse binding properties to examine adoptive T cell responses. Gene Therapy 20 (2013) 634-44.
Thomas DL, Doty R, Tosic V, Liu J, Kranz DM, McFadden G, MacNeill AL, Roy EJ. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunology Immunotherapy 60 (2011) 1461-72.